IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden
· Delayed Price · Currency is SEK 3.065
+0.040 (1.32%)
Aug 22, 2025, 5:29 PM CET
IRLAB Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 53.64 | 66.92 | 111.31 | 252.78 | 401.9 | 277.01 | Upgrade
|
| Cash & Short-Term Investments | 53.64 | 66.92 | 111.31 | 252.78 | 401.9 | 277.01 | Upgrade
|
| Cash Growth | -45.41% | -39.88% | -55.96% | -37.10% | 45.08% | 150.63% | Upgrade
|
| Accounts Receivable | 8.43 | - | - | 3.32 | 4.47 | - | Upgrade
|
| Other Receivables | - | 10.08 | 9.17 | 8.9 | 6.27 | 4.71 | Upgrade
|
| Receivables | 8.43 | 10.08 | 9.17 | 12.22 | 10.74 | 4.71 | Upgrade
|
| Prepaid Expenses | - | 2.2 | 2.8 | 3.34 | 2.28 | 2.02 | Upgrade
|
| Other Current Assets | - | 0.37 | 0.31 | 0.35 | 6.52 | 0 | Upgrade
|
| Total Current Assets | 62.08 | 79.56 | 123.59 | 268.68 | 421.44 | 283.74 | Upgrade
|
| Property, Plant & Equipment | 7.56 | 9.79 | 6.67 | 8.01 | 8.35 | 4.32 | Upgrade
|
| Other Intangible Assets | 46.86 | 46.86 | 46.86 | 46.86 | 42.4 | 81.49 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 0.26 | 0.52 | Upgrade
|
| Other Long-Term Assets | -0 | -0 | - | -0 | -0 | - | Upgrade
|
| Total Assets | 116.5 | 136.21 | 177.12 | 323.56 | 472.45 | 370.07 | Upgrade
|
| Accounts Payable | - | 9.94 | 10.52 | 10.03 | 12.3 | 3.68 | Upgrade
|
| Accrued Expenses | - | 11.68 | 14.91 | 13.44 | 5.84 | 11.81 | Upgrade
|
| Short-Term Debt | 18.8 | 53.47 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 3.42 | 3.42 | 2.94 | 3.6 | 3.03 | 1.66 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 42.58 | - | Upgrade
|
| Other Current Liabilities | 68.43 | 21.54 | 8.35 | 5.28 | 5.65 | 3.77 | Upgrade
|
| Total Current Liabilities | 142.38 | 100.04 | 36.73 | 32.34 | 69.4 | 20.92 | Upgrade
|
| Long-Term Debt | - | - | 24.51 | - | - | - | Upgrade
|
| Long-Term Leases | 1.8 | 3.54 | 0.12 | 0.38 | 3.57 | 1.27 | Upgrade
|
| Other Long-Term Liabilities | -0 | - | - | - | - | - | Upgrade
|
| Total Liabilities | 144.18 | 103.58 | 61.36 | 32.72 | 72.97 | 22.19 | Upgrade
|
| Common Stock | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 0.97 | Upgrade
|
| Additional Paid-In Capital | 696.17 | 690.21 | 690.21 | 690.21 | 685.45 | 685.63 | Upgrade
|
| Retained Earnings | -724.89 | -658.61 | -575.48 | -400.41 | -287 | -338.79 | Upgrade
|
| Comprehensive Income & Other | 0 | 0 | - | - | - | 0.07 | Upgrade
|
| Total Common Equity | -27.68 | 32.64 | 115.76 | 290.83 | 399.48 | 347.88 | Upgrade
|
| Shareholders' Equity | -27.68 | 32.64 | 115.76 | 290.83 | 399.48 | 347.88 | Upgrade
|
| Total Liabilities & Equity | 116.5 | 136.21 | 177.12 | 323.56 | 472.45 | 370.07 | Upgrade
|
| Total Debt | 75.76 | 60.42 | 27.57 | 3.98 | 6.6 | 2.93 | Upgrade
|
| Net Cash (Debt) | -22.11 | 6.5 | 83.74 | 248.8 | 395.3 | 274.08 | Upgrade
|
| Net Cash Growth | - | -92.24% | -66.34% | -37.06% | 44.23% | 158.61% | Upgrade
|
| Net Cash Per Share | -0.43 | 0.13 | 1.61 | 4.80 | 7.64 | 5.75 | Upgrade
|
| Filing Date Shares Outstanding | 51.87 | 51.87 | 51.87 | 51.87 | 51.75 | 51.75 | Upgrade
|
| Total Common Shares Outstanding | 51.87 | 51.87 | 51.87 | 51.87 | 51.75 | 51.75 | Upgrade
|
| Working Capital | -80.31 | -20.48 | 86.86 | 236.34 | 352.04 | 262.82 | Upgrade
|
| Book Value Per Share | -0.53 | 0.63 | 2.23 | 5.61 | 7.72 | 6.72 | Upgrade
|
| Tangible Book Value | -74.55 | -14.23 | 68.9 | 243.97 | 357.08 | 266.39 | Upgrade
|
| Tangible Book Value Per Share | -1.44 | -0.27 | 1.33 | 4.70 | 6.90 | 5.15 | Upgrade
|
| Machinery | - | 7.02 | 6.82 | 6.53 | 3.65 | 2.94 | Upgrade
|
| Leasehold Improvements | - | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.